Addressing Negative and Cognitive Symptoms in Schizophrenia: A Focus on Digital Therapeutics

Dates and Times

Start: 10/21/2025 11:00 AM
End: 10/21/2025 12:00 PM

Objectives

1.  Learn about recent data supporting the efficacy of muscarinic acetylcholine receptor agonists and positive allosteric modulators for treatment of schizophrenia.

2.  Understand the mechanistic underpinnings and roles of specific muscarinic receptor subtypes in efficacy in reducing different symptoms in schizophrenia patients.

Speakers

Location

Stony Brook University
101 Nicolls Rd.
HSC, Level Level 2, Lecture Hall 2
Stony Brook, NY 11794

Accreditation

The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits ^™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.